EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

Julian Peter Müller iD, Vladimir N Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L Cornelius Bollheimer, Julia C Stingl, Katja S Just iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70631 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Julian Peter Müller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany. Hauptthemen laut MEDLINE: Pantoprazole, Cytochrome P-450 CYP2C19, Proton Pump Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Aachen, B. Braun-Stiftung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted. The aim of this work was to validate pantoprazole as a CYP2C19 phenotyping drug.

Methods

We performed a single‐dose pharmacokinetic study with 20 healthy participants in a randomized cross‐over design. Participants received 10 mg omeprazole and 20 mg pantoprazole on two different study days with a washout phase of one week. Blood sampling was performed at 14 time points spanning 8 h after drug administration. Drug and metabolite plasma concentrations were assessed by LC–MS/MS. Metabolic ratios (MR) of metabolite/substrate were formed using the area under the curve from 0 to 8 h (AUC 0‐8h ) and single plasma concentrations.

Results

We demonstrate very strong correlations (Spearman ρ = 0.84) of AUC 0‐8h MR 4‐desmethylpantoprazole‐sulfate/pantoprazole to the validated CYP2C19 probe AUC 0‐8h MR 5‐hydroxyomeprazole/omeprazole (Spearman ρ = 0.84). Single time point pantoprazole MRs measured in plasma between 4 and 8 h after pantoprazole administration were sufficient for accurate CYP2C19 phenotyping by demonstrating significant and robust correlations to the AUC 0‐8h MR 5‐hydroxyomeprazole/omeprazole with Spearman ρ ≥ 0.8.

Conclusions

In contrast to omeprazole, pharmacokinetics of pantoprazole are described to be stable during repeated dosing, which may allow phenotyping of CYP2C19 with patients using pantoprazole MRs in situations where pantoprazole is part of the prescribed medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PantoprazoleCytochrome P-450 CYP2C19Proton Pump InhibitorsCytochrome P-450 CYP2C19 InhibitorsHumansCross-Over StudiesMalePhenotypeFemaleOmeprazoleAdultArea Under CurveYoung AdultTandem Mass Spectrometry

Stichwörter der Autor:innen

CYP2C19cytochrome P450drug–drug interactionspersonalized medicinepharmacogeneticspharmacokinetics

Substanzen

PantoprazoleCytochrome P-450 CYP2C19CYP2C19 protein, humanOmeprazoleProton Pump InhibitorsCytochrome P-450 CYP2C19 Inhibitors

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of NanoBiophotonics, Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), Göttingen, Lower Saxony, Germany.
  • Department of Geriatric Medicine, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of Geriatrics, Carl von Ossietzky University of Oldenburg, Oldenburg, Lower Saxony, Germany.
  • Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany.

ORCID-Profile: Julian Peter Müller, Katja S Just

Förderung

  • Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Aachen
  • B. Braun-Stiftung
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Müller, J. P., Belov, V. N., Yamoune, S., Miller, B., Hasoumi, M., Tupiec, J., Laurentius, T., Bollheimer, L. C., Stingl, J. C., & Just, K. S. (2026). Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70631

Vancouver

Müller JP, Belov VN, Yamoune S, Miller B, Hasoumi M, Tupiec J, et al. Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70631

BibTeX
@article{Mller2026,
  author = {Müller, Julian Peter and Belov, Vladimir N and Yamoune, Sabrina and Miller, Bob and Hasoumi, Mohammed and Tupiec, Jolanta and Laurentius, Thea and Bollheimer, L Cornelius and Stingl, Julia C and Just, Katja S},
  title = {Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70631}
}
Kostenlos starten →